Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANTURANE vs TROMETHAMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
Tromethamine is a proton acceptor that buffers hydrogen ions, correcting metabolic acidosis by increasing bicarbonate and base excess. It acts as a weak base with high buffering capacity.
Treatment of chronic gout,Prophylaxis of acute gouty attacks during initiation of allopurinol or uricosuric therapy,Off-label: Prevention of calcium oxalate calculi in hyperuricosuric patients
Metabolic acidosis associated with cardiac arrest,Correction of metabolic acidosis in acute respiratory acidosis,Metabolic acidosis in renal failure,Metabolic acidosis in diabetes mellitus
200-400 mg orally twice daily
Intravenous: 1 M solution (3.6 g/30 m L) administered via central line; usual adult dose 300-500 mg/kg (0.27-0.45 g/kg) given over 1-2 hours; may be repeated based on blood gas monitoring.
Terminal elimination half-life is approximately 4–6 hours for the parent drug; active sulfide metabolite has a half-life of 12–16 hours. Clinically, twice-daily dosing maintains therapeutic levels.
Terminal elimination half-life: 2–3 hours in adults with normal renal function. May be prolonged in renal impairment.
Primarily hepatic oxidation and glucuronidation; minor CYP450 involvement.
Tromethamine is not metabolized; it is primarily excreted unchanged by the kidneys.
Renal excretion: approximately 50% of the dose as unchanged drug and its active sulfide metabolite via glomerular filtration and tubular secretion; biliary/fecal: ~30%, primarily as metabolites.
Renal excretion of unchanged drug: >95%. Negligible biliary or fecal elimination.
99% bound, primarily to albumin.
<10% bound to plasma proteins (albumin).
0.15–0.3 L/kg, indicating limited extravascular distribution; primarily remains in plasma and extracellular fluid.
0.3–0.4 L/kg; primarily distributes in extracellular fluid.
Oral: Approximately 90% absorbed, but extensive first-pass metabolism reduces systemic bioavailability of parent drug to 30–40%; active sulfide metabolite contributes to efficacy.
Not available (administered intravenously only; oral bioavailability is negligible due to lack of absorption).
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-50 m L/min, reduce dose by 50%. For Cr Cl >50 m L/min, no adjustment.
Contraindicated in anuria or severe renal impairment (GFR < 30 m L/min). Use with caution in renal insufficiency; monitor acid-base balance. No specific dose adjustment guidelines; avoid in renal failure.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
No specific Child-Pugh based dose adjustments; use with caution in hepatic impairment as metabolism is minimal (primarily renal excretion). Monitor electrolytes and p H.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Intravenous: 1 M solution; dose based on calculated base deficit: m L of 0.3 M THAM = body weight (kg) × base deficit (m Eq/L) × 1.1. Administer over 1-2 hours via central line. Maximum infusion rate: 5 m L/kg/hour.
Start at low end of dosing range (200 mg twice daily); monitor renal function. Caution due to increased sensitivity and renal impairment.
No specific dose adjustment; monitor renal function and avoid in geriatric patients with renal impairment due to decreased creatinine clearance. Use lower end of dosing range and monitor acid-base status frequently.
None.
There is no FDA black box warning for tromethamine.
Acute gouty attacks may occur during initiation; prophylactic colchicine or NSAIDs recommended,Monitor renal function; dose adjustment in renal impairment,Avoid in patients with high urinary uric acid output to prevent uric acid stones,May potentiate warfarin; monitor INR,Cross-allergenicity with sulfonamides possible
Monitor blood p H, p CO2, and electrolytes (especially potassium) during infusion,Use with caution in patients with renal impairment due to risk of accumulation,May cause respiratory depression, especially in patients with impaired renal function,Avoid extravasation due to tissue necrosis,Not recommended for neonatal use due to risk of hyperosmolality
Severe renal impairment (Cr Cl <50 m L/min),History of hypersensitivity to sulfinpyrazone or sulfonamides,Active peptic ulcer disease,Blood dyscrasias,Uric acid nephropathy or stone formation
Anuria or uremia,Chronic respiratory acidosis,Hypoglycemia,Hyperkalemia,Hypocalcemia,Known hypersensitivity to tromethamine
Avoid alcohol as it increases uric acid levels and may decrease drug efficacy. Maintain adequate hydration; avoid excessive intake of high-purine foods (e.g., organ meats, sardines, anchovies) to help control gout.
No known food interactions. However, electrolyte imbalances (e.g., hypokalemia) may be affected by dietary potassium intake; maintain a balanced diet per clinician advice.
Anturane (sulfinpyrazone) is a uricosuric agent. There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 10 times the human dose. However, due to its potential to inhibit platelet aggregation, use during pregnancy, especially near term, may increase the risk of maternal and fetal hemorrhage. First trimester: No specific fetal risks identified, but caution advised. Second trimester: Risks unclear; avoid unless necessary. Third trimester: Potential for premature closure of ductus arteriosus (unlikely as it is not an NSAID) and bleeding risk; avoid near term.
Tromethamine is a parenteral alkalinizing agent used in metabolic acidosis. Animal reproduction studies have not been conducted. It is not known whether tromethamine can cause fetal harm when administered to a pregnant woman. Use during pregnancy only if clearly needed. Risk cannot be ruled out.
Sulfinpyrazone is excreted into human milk in small amounts. The milk-to-plasma (M/P) ratio is not well established but is likely low (<0.2). Due to potential adverse effects in the nursing infant (e.g., bleeding risk, interference with platelet function), caution is recommended. The benefits of breastfeeding should be weighed against the potential risks, and alternative therapies considered.
It is not known whether tromethamine is excreted in human milk. The M/P ratio is undetermined. Caution should be exercised when administered to a nursing woman.
Pregnancy can alter pharmacokinetics of drugs due to increased plasma volume, renal blood flow, and hepatic metabolism. For sulfinpyrazone, no specific dose adjustment guidelines are established for pregnancy. Given its uricosuric action, the increased glomerular filtration rate during pregnancy may enhance clearance, potentially requiring higher doses to maintain therapeutic effect. However, due to potential risks, use should be avoided if possible. If used, monitor serum uric acid levels and adjust dose accordingly, starting with the lowest effective dose.
No specific dosing adjustments are recommended for pregnancy. However, pharmacokinetic changes in pregnancy (increased plasma volume, altered renal function) may necessitate careful monitoring and titration based on clinical and laboratory response.
Anturane (sulfinpyrazone) is a uricosuric agent used for chronic gout. It is contraindicated in patients with peptic ulcer disease due to GI irritation. Monitor renal function and uric acid levels. Avoid use in patients with a history of uric acid stones; maintain high fluid intake to prevent stone formation. Not effective in acute gout attacks. Discontinue at least 48 hours before surgery to avoid bleeding risk due to antiplatelet effects.
Tromethamine (THAM) is an amino alcohol that acts as a proton acceptor, used to correct metabolic acidosis when sodium bicarbonate is contraindicated (e.g., hypernatremia, hypercapnia). It is preferred in patients with lactic acidosis or respiratory acidosis because it does not generate CO2. Monitor serum potassium closely as it can cause hypokalemia. Extravasation causes tissue necrosis; administer via central line if possible. Correct dosing is based on base deficit: m L of 0.3 M THAM = base deficit (m Eq/L) × weight (kg) × 1.1.
Take with food or milk to reduce stomach upset.,Drink at least 8 glasses of water daily to prevent kidney stones.,Avoid aspirin and other salicylates as they reduce drug effectiveness.,Report any signs of bleeding (bruising, black stools) or stomach pain.,Do not stop suddenly without consulting your doctor.,This drug is not for acute gout attacks; continue other medications as prescribed.
This medication is used to treat acidosis (too much acid in the blood).,It is given intravenously (IV) by your healthcare provider.,Report any signs of IV site reaction: pain, redness, swelling, or blistering.,You may need frequent blood tests to monitor your acid-base balance and potassium levels.,Tell your doctor if you have kidney disease or low blood potassium before treatment.
No interactions on record
"Methotrimeprazine may reduce the gastrointestinal absorption of tromethamine, an alkalinizing agent, leading to decreased systemic exposure and potentially diminished therapeutic efficacy. This interaction is hypothesized to occur via altered gastric pH or motility, though direct evidence is limited. Patients may experience reduced effectiveness of tromethamine in managing acid-base disorders."
"Tromethamine, an alkalinizing agent used to correct metabolic acidosis, can increase gastric pH, which may reduce the absorption of weakly acidic drugs like estrone sulfate. This altered gastrointestinal environment can decrease estrone sulfate bioavailability, potentially compromising its systemic effects for hormone replacement therapy. Clinically, this may lead to reduced efficacy of estrone sulfate, requiring dose adjustments or alternative administration routes."
"Tromethamine, an alkalinizing agent, can increase urinary pH, which enhances the renal excretion of sotalol, a class III antiarrhythmic that is primarily eliminated unchanged by the kidneys. This interaction may lead to reduced serum sotalol concentrations, potentially decreasing its therapeutic efficacy and increasing the risk of arrhythmia recurrence, particularly in patients with renal impairment or those requiring precise antiarrhythmic control."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANTURANE vs TROMETHAMINE, answered by our medical review team.
ANTURANE is a Uricosuric that works by Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.. TROMETHAMINE is a Alkalinizing Agent (Buffer) that works by Tromethamine is a proton acceptor that buffers hydrogen ions, correcting metabolic acidosis by increasing bicarbonate and base excess. It acts as a weak base with high buffering capacity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANTURANE and TROMETHAMINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANTURANE is: 200-400 mg orally twice daily. The standard adult dose of TROMETHAMINE is: Intravenous: 1 M solution (3.6 g/30 m L) administered via central line; usual adult dose 300-500 mg/kg (0.27-0.45 g/kg) given over 1-2 hours; may be repeated based on blood gas monitoring.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANTURANE and TROMETHAMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANTURANE is classified as Category C. Anturane (sulfinpyrazone) is a uricosuric agent. There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at dos. TROMETHAMINE is classified as Category C. Tromethamine is a parenteral alkalinizing agent used in metabolic acidosis. Animal reproduction studies have not been conducted. It is not known whether tromethamine can cause feta. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.